Skip to Main Content

We have a knack in the U.S. for blurring behavior and medicine. Look at weight. For a long time, we’ve treated obesity as a moral failing, a lack of willpower. That was wrong. Now we’re treating weight as a medical issue that can be cured by pill or injection. Is this any better?

Up to 130 million Americans could qualify for Ozempic or other GLP-1s (glucagon-like peptides), which cost nearly $1,000 per month. Never have so many of us been eligible for such an expensive drug. But let’s be honest, even if it were free, is dosing a third to half of the U.S. population a good idea?

advertisement

Right now GLP-1s are providing not just moments of hope on scales in bathrooms but moments of reckoning in boardrooms. Many Americans are delighted that a monthly injection could offer a solution to obesity — no strict dieting or surgery necessary. Many companies are optimistic about the chance to improve the health of their employees, and, collectively, our country. But rightly, they have questions.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.